• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Envoy Medical Inc.

    5/11/26 6:02:15 PM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    ENVOY MEDICAL, INC.

    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    29415V109

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    29415V109


    1Names of Reporting Persons

    Ayrton Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,457,963.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,457,963.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,457,963.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.10 %
    12Type of Reporting Person (See Instructions)

    IA, CO


    SCHEDULE 13G

    CUSIP Number(s):
    29415V109


    1Names of Reporting Persons

    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,457,963.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,457,963.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,457,963.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.10 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    29415V109


    1Names of Reporting Persons

    Waqas Khatri
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,457,963.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,457,963.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,457,963.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.10 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENVOY MEDICAL, INC.
    (b)Address of issuer's principal executive offices:

    4875 White Bear Parkway, White Bear Lake, MN 55110
    Item 2. 
    (a)Name of person filing:

    (i) Ayrton Capital LLC; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B; and (iii) Waqas Khatri
    (b)Address or principal business office or, if none, residence:

    (i) Ayrton Capital LLC, 55 Post Rd West, 2nd Floor Westport, CT 06880; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, Suite #7 Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman, P.O. Box 10250, Cayman Islands; and (iii) Waqas Khatri 55 Post Rd West, 2nd Floor Westport, CT 06880
    (c)Citizenship:

    (i) Ayrton Capital LLC: United States; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: Cayman Islands; and (iii) Waqas Khatri: United States
    (d)Title of class of securities:

    Class A Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    29415V109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Ayrton Capital LLC: 2,457,963 ; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 2,457,963 ; and (iii) Waqas Khatri: 2,457,963. Represents 2,457,963 shares of Common Stock issuable on the exercise of certain warrants (the "Warrants") held by the Reporting Persons. The issuable shares of Common Stock related to the exercise of the Warrants are subject to a 9.99% beneficial ownership blocker. The shares reported herein represent Common Stock of ENVOY MEDICAL, INC. (the "Issuer") held by Alto Opportunity Master Fund, SPC- Segregated Master Portfolio B, a Cayman Islands exempted company (the "Fund"). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the "Investment Manager"), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the "Reporting Persons").
    (b)Percent of class:

    The percentages below are based on (i) 76,881,110 shares of Common Stock of the Issuer that were outstanding as of March 20, 2026; and (ii) 2,457,963 shares of Common Stock issuable on the exercise of the Warrants held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer's 10-K filed on March 23, 2026. For the sake of clarity, the holdings of the Reporting Persons reported herein are as of March 31, 2026 . (i) Ayrton Capital LLC: 3.10%; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 3.10%; and (iii) Waqas Khatri: 3.10%.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 2,457,963 ; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 2,457,963 ; and (iii) Waqas Khatri: 2,457,963

     (ii) Shared power to vote or to direct the vote:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; and (iii) Waqas Khatri: 0

     (iii) Sole power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 2,457,963 ; Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 2,457,963 ; Waqas Khatri: 2,457,963

     (iv) Shared power to dispose or to direct the disposition of:

    (i) Ayrton Capital LLC: 0; (ii) Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B: 0; (iii) Waqas Khatri: 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ayrton Capital LLC
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Managing Member
    Date:05/11/2026
     
    Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri / Director
    Date:05/11/2026
     
    Waqas Khatri
     
    Signature:/s/ Waqas Khatri
    Name/Title:Waqas Khatri
    Date:05/11/2026
    Get the next $COCH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    3/31/2026$2.50Buy
    H.C. Wainwright
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    SEC Filings

    View All

    Envoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    5/22/26 4:05:31 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    5/18/26 4:05:41 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form SCHEDULE 13G filed by Envoy Medical Inc.

    SCHEDULE 13G - Envoy Medical, Inc. (0001840877) (Subject)

    5/15/26 4:41:37 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th

    White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ:COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026Location: Bellagio Hotel & Casino, Las Vegas, NVBooth: #410Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M. PTPresentation Location: Track 7 - Donatello 3Webcast: Viewable hereThe Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedul

    6/4/26 8:30:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology

    Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge SafetyWhite Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ:COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant industry. "As we continue advancing fully implanted hearing technology, protecting the innovation beh

    5/20/26 8:30:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant

    Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry ConferencesWhite Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant."The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and th

    5/11/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

    Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

    6/24/24 7:29:10 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lucas Brent T. was granted 32,856 shares, increasing direct ownership by 11% to 329,946 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/4/26 4:28:22 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Mckhann Chas

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    4/17/26 4:32:04 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Mckhann Chas

    3 - Envoy Medical, Inc. (0001840877) (Issuer)

    4/17/26 4:31:30 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Leadership Updates

    Live Leadership Updates

    View All

    Envoy Medical Appoints Chas McKhann to Board of Directors

    Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful ExitsWhite Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors.Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder valu

    4/16/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

    Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

    8/26/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

    WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

    6/11/24 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Financials

    Live finance-specific insights

    View All

    Envoy Medical Reports on Second Quarter 2025 Results

    White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A

    7/31/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports on First Quarter 2025 Results

    Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

    5/1/25 4:30:00 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

    Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

    3/31/25 9:15:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/14/24 8:49:34 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/13/24 4:40:10 PM ET
    $COCH
    Industrial Specialties
    Health Care